High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria

Thrombosis and Haemostasis

Volumn 82, Issue 3, 1999, Pages 1020-1023

  Ariëns, Robert A S ^a   Moia, M ^b   Rivolta, E ^b   Ponticelli, C ^b   Mannucci, P M ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTITHROMBIN; HEPARIN; PROTEIN C; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEINURIA; THROMBOGENESIS;

EID: 0032844317     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614322     Document Type: Article

References (33)

1. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrolic syndrome. Kidney Int 1985; 28: 429-39.
2. Rahelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-96.
3. Kauffman RH, Veltkamp JJ, van Tilburg NH, van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-13.
4. Boneu B, Bouissou F, Abbal M, Sie P, Caranobe C, Barthe P. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome. Thromb Haemost 1981; 46: 623-5.
5. Vaziri ND, Paule P, Toohey J, Hung E, Alikhani S, Drawish R, Pahl M. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Int Med 1984; 144: 1802-3.
6. Vigano-D'Angelo S, D'Angelo A, Kaufman CE, Scholer C, Esmon CT, Comp PC. Protein S deficiency occurs in the nephrotic syndrome. Ann Int Med 1987; 170: 42-7.
7. Gouault-Heilmann M, Gadelha-Parente T, Levent M, Intrator L, Rostoker G, Lagrue G. Total and free protein S in nephrotic syndrome. Thromb Res 1988; 49: 37-42.
8. Rydzewski A, Mysliwiec M, Soszka J. Concentration of three thrombin inhibitors in the nephrotic syndrome in adults. Nephron 1986; 42: 200-3.
9. Toulon P, Gandrille S, Remy, P, Chadeuf G, Jouvin MH, Aiach M. Significance of high levels of heparin cofactor II in the plasma and urine of adult patients with nephrotic syndrome. Nephron 1992; 60: 176-80.
10. Soff GA, Sica DA, Marlar RA, Evans HJ, Qureshi GD. Protein C levels in nephrotic syndrome: Use of a new enzyme-linked immunosorbent assay for protein C antigen. Am J Hematol 1986; 22: 43-9.
11. Cosio FG, Harker C, Batard MA, Brandt JT, Griffin JH. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med 1985; 106: 218-22.
12. Pabinger-Fashing I, Lechner K, Niessner H, Schmidt P, Balzar E, Mannhalter CH. High levels of plasma protein C in nephrotic syndrome. Thromb Haemost 1985; 53: 5-7.
13. Mannucci PM, Valsecchi C, Bottasso B, D'Angelo A, Casati S, Ponticelli C. High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemost 1986; 55: 31-3.
14. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
15. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
16. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-49.
17. Salvesen G, Pizzo SV. Proteinase Inhibitors: α-Macroglobulins, Serpins and Kunins. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW, eds.Philadelphia, PA: J. B. Lippincott Company 1994; pp. 241-58.
18. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
19. Ariëns RAS, Faioni EM, Mannucci PM. Repeated release of the tissue factor pathway inhibitor. Thromb Haemost 1994; 72: 327-8.
20. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77: 408-23.
21. Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiological role for EPI as a natural anticoagulant. Proc Nat Acad Sci USA 1991; 88: 708-12.
22. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991; 78: 1496-502.
23. Ariëns RAS, Alberto G, Moia M, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 203-7.
24. Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 1987; 46: 527-37.
25. Novotny WF, Girard JP, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
26. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-9.
27. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol. Blood Coag Fibrinol 1991; 2: 425-33.
28. Marsh JB, Drabkin DL. Experimental reconstruction of metabolic pattern of lipid nephrosis: Key role of hepatic protein synthesis in hyperlipidemia. Metabolism 1960; 9: 946-55.
29. Alexander JH, Schapel GJ, Edwards KDG. Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 1974; 2: 119-22.
30. Appel GB, Valeri A, Appel AS, Blum C. The hyperlipidemia of the nephrotic syndrome. Am J Med 1989; 87: 45N-50N.
31. Deen WM, Meyers BD, Brenner BM. The glomerular barrier to macromolecules, theoretical and experimental considerations. In: Nephrotic Syndrome. Brenner BM, Stein JH, eds. New York: Churchill Livingstone 1982; pp. 1-29.
32. Girot RF, Jaubert F, Leon M, Bellon B, Aiach M, Josso F, Lepelletier O, Beguin S, Monnet JP. Albumin, fibrinogen, prothrombin and antithrombin III variations in blood, urines and liver in rat nephrotic syndrome. Thromb Haemost 1983; 49: 13-7.
33. Ibarra-Rubbio ME, Pedraza-Chaverri J, Panduro A. Differential regulation in the expression of hepatic genes in nephrotic and pair-fed rats. Nephron 1993; 65: 119-24.